You are here: Industry Insights > Aldevron

News List

Aldevron, Ginkgo Bioworks Partner on mRNA Vax Mfg. Breakthrough contractpharma
August 12, 2021
Achieved improvements in manufacturing yield of vaccinia capping enzyme (VCE), a component often required to produce mRNA therapies and vaccines.
AavantiBio, Aldevron Form Gene Therapy Partnership contractpharma
July 28, 2021
Aldevron will supply plasmids to AavantiBio’s planned vector core and CDMO partners.
Danaher To Acquire Aldevron for $9.6B contractpharma
June 22, 2021
Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.
Danaher to acquire Aldevron from EQT for $9.6bn pharmaceutical-business-review
June 18, 2021
Danaher, a science and technology company, has agreed to acquire biotech firm Aldevron from EQT Private Equity for an enterprise value of $9.bn.
Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline americanpharmaceuticalreview
May 28, 2021
Moderna a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing ...
Genprex Partner Aldevron Completes Step in Mfg. for Oncoprex Clinical Devt. Program contractpharma
August 12, 2019
Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex in combination with targeted therapies and immunotherapies.
Aldevron to Build 14-Acre Gene Therapy Mfg. Campus contractpharma
June 04, 2019
Annual capacity will exceed $1 billion of plasmid DNA, RNA, gene editing enzymes, and other biologics.
Aldevron Readies for Expansion contractpharma
May 16, 2019
Announces 1,000 liter fermentation capacity and significant manufacturing space growth.
Oxford Genetics wins six licensing deals pharmatimes
April 04, 2019
In the last twelve months, Oxford Genetics has won six new licensing deals for its scalable gene therapy manufacturing technologies.